Skip to content
Benefits & EvidenceEvidence-Tiered

Adrenomedullin Benefits

What does Adrenomedullin actually do? We break down the evidence by tier — human data, animal studies, and in vitro research — with citations for every claim.

Quick Answer

Adrenomedullin offers potent vasodilation, endothelial barrier stabilization, and cardioprotection. It is a promising therapeutic target for sepsis and heart failure. Its measurement, via MR-proADM, is a valuable prognostic biomarker. Preclinical studies suggest anti-inflammatory and antimicrobial effects. Clinical trials are investigating its potential to improve outcomes in severe cardiovascular conditions.

→ Adrenomedullin Dosage→ Adrenomedullin Side Effects→ Full Adrenomedullin Profile

Evidence Tiers

HumanClinical or observational human dataAnimalPreclinical in vivo studiesIn VitroCell / tissue culture studies
Table of Contents

Mechanism of Action

Adrenomedullin activates the CLR/RAMP2 and CLR/RAMP3 receptor complexes, increasing cAMP and nitric oxide production, leading to vasodilation. It enhances endothelial barrier integrity by modulating tight junctions and adherens junctions. It also reduces cardiomyocyte apoptosis through PI3K/Akt signaling and suppresses inflammatory cytokine release. Its antimicrobial effects are due to membrane disruption.

Human Evidence

Human2 findings

Endothelial barrier stabilization in sepsis

Clinical trials with Adrecizumab (anti-adrenomedullin antibody) show improved endothelial barrier function and reduced organ failure in septic shock patients.

PubMed 32125225 (2020) ↗

Prognostic biomarker in heart failure

Elevated MR-proADM levels are associated with increased mortality and adverse outcomes in patients with acute and chronic heart failure.

PubMed 24735463 (2014) ↗

Animal Studies

Animal3 findings

Cardioprotection in ischemia-reperfusion injury

Animal studies demonstrate that adrenomedullin reduces cardiomyocyte apoptosis and cardiac fibrosis following ischemia-reperfusion injury.

PubMed 16198366 (2005) ↗

Reduced pulmonary edema in acute lung injury

Adrenomedullin administration in animal models of acute lung injury reduces pulmonary edema and improves oxygenation.

PubMed 17303726 (2007) ↗

Improved survival in sepsis models

Adrenomedullin and related therapies have shown improved survival rates in animal models of sepsis by mitigating endothelial dysfunction and organ damage.

PubMed 20164581 (2010) ↗

In Vitro Research

In Vitro2 findings
In vitro (cell culture) findings are the earliest stage of evidence. They indicate mechanism plausibility but cannot confirm human effects.

Enhanced endothelial barrier function

In vitro studies show that adrenomedullin strengthens endothelial cell tight junctions and adherens junctions, reducing vascular permeability.

PubMed 19815995 (2009) ↗

Anti-inflammatory effects on macrophages

Adrenomedullin suppresses the release of pro-inflammatory cytokines (TNF-α, IL-6) from macrophages in vitro.

PubMed 15890524 (2005) ↗

What's Proven vs What's Still Unknown

✓ What the Evidence Supports

  • ✓Potent vasodilation
  • ✓Endothelial barrier stabilization in sepsis (via Adrecizumab)
  • ✓Prognostic biomarker for sepsis and heart failure (MR-proADM)
  • ✓Cardioprotective effects in animal models

? Still Unknown or Unconfirmed

  • ?Optimal dosing regimen for long-term cardioprotection
  • ?Efficacy in specific subgroups of sepsis patients
  • ?Long-term safety profile of Adrecizumab

Frequently Asked Questions

What are the main benefits of adrenomedullin?
The key benefits include potent vasodilation, endothelial barrier stabilization (particularly in sepsis), and cardioprotection. It also serves as a prognostic biomarker for cardiovascular risk.
How does adrenomedullin protect the heart?
Adrenomedullin reduces cardiomyocyte apoptosis and cardiac fibrosis following ischemia-reperfusion injury, as demonstrated in animal studies.
What is the role of adrenomedullin in sepsis?
Adrenomedullin stabilizes the endothelial barrier, preventing vascular leak and organ damage in sepsis. Adrecizumab, an anti-adrenomedullin antibody, enhances this effect.
What does MR-proADM tell us?
MR-proADM is a stable surrogate for adrenomedullin levels and serves as a prognostic biomarker. Elevated levels indicate a higher risk of adverse outcomes in sepsis, pneumonia, and heart failure.
Is adrenomedullin a viable therapeutic target?
Yes, adrenomedullin-targeted therapies, such as Adrecizumab, are under clinical investigation for septic shock, showing promise in reducing organ failure.

References

  1. 1
    Adrenomedullin in cardiovascular disease: from bench to bedside(2005)PubMed ↗
  2. 2
    Mid-regional pro-adrenomedullin as a prognostic biomarker in sepsis: systematic review(2014)PubMed ↗
  3. 3
    Adrecizumab (anti-adrenomedullin antibody) in sepsis: AdrenOSS-2 trial results(2020)PubMed ↗
  4. 4
    Adrenomedullin protects against hypoxia-induced pulmonary edema(2007)PubMed ↗

Last updated: 2026-02-19